# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Charles Rhyee maintains Veradigm (OTC:MDRX) with a Buy and lowers the price target from $26 to $15.
Deutsche Bank analyst George Hill downgrades Veradigm (OTC:MDRX) from Buy to Hold and lowers the price target from $15 to $10.
Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is n...
The transaction will be funded through cash on hand and is not subject to a financing condition. The purchase price to be paid ...
The Company also announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan in an...
Veradigm Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANS...
RBC Capital analyst Sean Dodge maintains Veradigm (NASDAQ:MDRX) with a Outperform and lowers the price target from $22 to $11.